Literature DB >> 18022314

Estrogen stimulates transcription from the human prolactin distal promoter through AP1 and estrogen responsive elements in T47D human breast cancer cells.

Renqin Duan1, Erika Ginsburg, Barbara K Vonderhaar.   

Abstract

Human prolactin (hPRL) is a pleiotropic and versatile hormone that exercises more than 300 biological activities through binding to its cognate receptors. Recently, multiple studies have implicated hPRL in the development of human breast cancer. As a target of hPRL, both normal and neoplastic human breast cells also synthesize and secrete hPRL, which therefore establishes an autocrine/paracrine action loop in the mammary gland. In contrast to the extensive studies of regulation of hPRL expression in the pituitary gland, regulation of hPRL in mammary tissue and human breast cancer cells has not been extensively addressed. Extrapituitary PRL expression is primarily regulated by a distal promoter located 5.8 kb upstream to the pituitary promoter. As a result of alternative promoter usage, extrapituitary PRL is regulated by different signalling pathways and different hormones, cytokines or neuropeptides compared to regulation in the pituitary. Here, we present evidence that shows estrogen directly induces hPRL gene expression in T47D human breast cancer cells. We have identified a functional, non-canonical estrogen responsive element (ERE) and an AP1 site located in the hPRL distal promoter. Gel shift and chromatin immunoprecipitation assays demonstrated that both estrogen receptor (ER)alpha and ERbeta directly bind to the ERE. However, only ERalpha interacts with AP1 proteins that bind to the AP1 site in the hPRL distal promoter. Promoter-reporter gene studies demonstrate that both ERE and AP1 sites are required for full induction of the promoter activity by estradiol. Our studies suggest that the interactions between estrogens, ERs, the ERE and AP1 transcription factors in regulation of autocrine/paracrine PRL in the human breast may be critical for oncogenesis and may contribute to progression of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18022314     DOI: 10.1016/j.mce.2007.10.004

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  16 in total

1.  Estrogen increases the transcription of human α2-Heremans-Schmid-glycoprotein by an interplay of estrogen receptor α and activator protein-1.

Authors:  C Qiu; X Liu; J Wang; Y Zhao; Q Fu
Journal:  Osteoporos Int       Date:  2014-02-07       Impact factor: 4.507

2.  Progesterone induces expression of the prolactin receptor gene through cooperative action of Sp1 and C/EBP.

Authors:  Anita S Goldhar; Renqin Duan; Erika Ginsburg; Barbara K Vonderhaar
Journal:  Mol Cell Endocrinol       Date:  2011-01-14       Impact factor: 4.102

3.  Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland.

Authors:  J M Faupel-Badger; M E Sherman; M Garcia-Closas; M M Gaudet; R T Falk; A Andaya; R M Pfeiffer; X R Yang; J Lissowska; L A Brinton; B Peplonska; B K Vonderhaar; J D Figueroa
Journal:  Br J Cancer       Date:  2010-08-24       Impact factor: 7.640

Review 4.  Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways.

Authors:  Stephen Safe; Kyounghyun Kim; Kyoungkim Kim
Journal:  J Mol Endocrinol       Date:  2008-09-04       Impact factor: 5.098

5.  Complex prolactin crosstalk in breast cancer: new therapeutic implications.

Authors:  Kristopher C Carver; Lisa M Arendt; Linda A Schuler
Journal:  Mol Cell Endocrinol       Date:  2009-04-01       Impact factor: 4.102

6.  Genetic variation in PRL and PRLR, and relationships with serum prolactin levels and breast cancer risk: results from a population-based case-control study in Poland.

Authors:  Sarah J Nyante; Jessica M Faupel-Badger; Mark E Sherman; Ruth M Pfeiffer; Mia M Gaudet; Roni T Falk; Abegail A Andaya; Jolanta Lissowska; Louise A Brinton; Beata Peplonska; Barbara K Vonderhaar; Stephen Chanock; Montserrat Garcia-Closas; Jonine D Figueroa
Journal:  Breast Cancer Res       Date:  2011-04-06       Impact factor: 6.466

7.  Calcitriol restores antiestrogen responsiveness in estrogen receptor negative breast cancer cells: a potential new therapeutic approach.

Authors:  Nancy Santos-Martínez; Lorenza Díaz; David Ordaz-Rosado; Janice García-Quiroz; David Barrera; Euclides Avila; Ali Halhali; Heriberto Medina-Franco; María J Ibarra-Sánchez; José Esparza-López; Javier Camacho; Fernando Larrea; Rocío García-Becerra
Journal:  BMC Cancer       Date:  2014-03-29       Impact factor: 4.430

8.  Role of Estrogen Response Element in the Human Prolactin Gene: Transcriptional Response and Timing.

Authors:  Anne V McNamara; Antony D Adamson; Lee S S Dunham; Sabrina Semprini; David G Spiller; Alan S McNeilly; John J Mullins; Julian R E Davis; Michael R H White
Journal:  Mol Endocrinol       Date:  2015-12-21

9.  Prolactin expression in the cochlea of aged BALB/c mice is gender biased and correlates to loss of bone mineral density and hearing loss.

Authors:  Robert J Marano; Jennifer Tickner; Sharon L Redmond
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

10.  An integrative method to decode regulatory logics in gene transcription.

Authors:  Bin Yan; Daogang Guan; Chao Wang; Junwen Wang; Bing He; Jing Qin; Kenneth R Boheler; Aiping Lu; Ge Zhang; Hailong Zhu
Journal:  Nat Commun       Date:  2017-10-19       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.